I agree with you to a degree, Peter. However, there is no pressing reason to approve Bydureon immediately. There are Byetta, Victoza already on the market. It's not going to be approved unlesss the question is resolved. As one FDA official said, the 3rd and 4th drug in the same class are tougher to get approved.
Market Data 
Markets 
AI
